Shijiazhuang Yiling Pharmaceutical Co., Ltd., commonly referred to as Yiling Pharmaceutical, is a leading player in the Chinese pharmaceutical industry, headquartered in Shijiazhuang, CN. Established in 1992, the company has made significant strides in the development and production of traditional Chinese medicine and modern pharmaceuticals, focusing on areas such as cardiovascular health, oncology, and respiratory diseases. Yiling Pharmaceutical is renowned for its innovative core products, including the widely acclaimed Yiling Qingfei Paidu Decoction, which exemplifies the integration of traditional practices with contemporary science. With a strong commitment to research and development, the company has achieved notable milestones, positioning itself as a trusted name in both domestic and international markets. Its dedication to quality and efficacy has earned Yiling Pharmaceutical a prominent market position, making it a key contributor to the advancement of healthcare solutions.
How does Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Shijiazhuang Yiling Pharmaceutical Co., Ltd. reported a carbon intensity of approximately 0.33 tonnes CO2e per million USD in revenue. For 2024, the company aims to achieve a carbon intensity of about 0.008 tonnes CO2e per million USD in revenue. While specific absolute emissions data for Scope 1, 2, and 3 are not disclosed, the company has set ambitious reduction targets for its emissions. Shijiazhuang Yiling Pharmaceutical has committed to reducing its Scope 1 emissions by 50% from 2020 levels by 2025 and aims to achieve net zero for Scope 1 emissions by 2030. Additionally, the company plans to reduce its Scope 2 emissions by 50% from 2020 levels by 2025 and also targets net zero for Scope 2 emissions by 2030. These commitments reflect a proactive approach to climate action and align with industry standards for sustainability. The company's climate initiatives are not cascaded from a parent organisation, indicating that these targets and data are independently established. Shijiazhuang Yiling Pharmaceutical's efforts contribute to the broader pharmaceutical industry's movement towards reducing carbon footprints and enhancing environmental responsibility.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shijiazhuang Yiling Pharmaceutical Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.